Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.57 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.57 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7195324 | 0.90 | FFAR1 (0.60) | CYSLTR1GPBAR1CYSLTR2ALOX5FFAR1 | |
| SCHEMBL9053241 | 0.84 | CYSLTR1 (0.73) | CYSLTR1GPBAR1CYSLTR2ALOX5FFAR1 | |
| SCHEMBL6089121 | 0.82 | CYSLTR1 (0.69) | CYSLTR1GPBAR1CYSLTR2ALOX5FFAR1 | |
| SCHEMBL7807149 | 0.82 | FFAR1 (0.68) | CYSLTR1GPBAR1CYSLTR2ALOX5FFAR1 | |
| SCHEMBL9031804 | 0.81 | FFAR1 (0.55) | CYSLTR1GPBAR1CYSLTR2ALOX5FFAR1 | |
| SCHEMBL7458734 | 0.81 | CYSLTR1 (0.68) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL6584268 | 0.80 | FFAR1 (0.60) | CYSLTR1GPBAR1CYSLTR2ALOX5FFAR1 | |
| SCHEMBL9022221 | 0.79 | CYSLTR1 (0.67) | CYSLTR1GPBAR1CYSLTR2ALOX5FFAR1 | |
| SCHEMBL9428833 | 0.79 | ALOX5 (0.74) | CYSLTR1ALOX5FFAR1AKR1B1 | |
| SCHEMBL1419872 | 0.78 | FFAR1 (0.77) | CYSLTR1GPBAR1CYSLTR2ALOX5FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | claimed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | disclosed |
| WO-2018071687-A1 | METHODS OF TREATING PRURITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | CYSLTR1 3/4885GPBAR1 70/4885CYSLTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.